Istaroxime treatment ameliorates calcium dysregulation in a zebrafish model of phospholamban R14del cardiomyopathy

S. M. Kamel, C. J. M. van Opbergen, C. D. Koopman, A. O. Verkerk, B. J. D. Boukens, B. de Jonge, Y. L. Onderwater, E. van Alebeek, S. Chocron, C. Polidoro Pontalti, W. J. Weuring, M. A. Vos, T. P. de Boer, T. A. B. van Veen, J. Bakkers

Research output: Contribution to journalArticleAcademicpeer-review

16 Citations (Scopus)

Abstract

The heterozygous Phospholamban p.Arg14del mutation is found in patients with dilated or arrhythmogenic cardiomyopathy. This mutation triggers cardiac contractile dysfunction and arrhythmogenesis by affecting intracellular Ca2+ dynamics. Little is known about the physiological processes preceding induced cardiomyopathy, which is characterized by sub-epicardial accumulation of fibrofatty tissue, and a specific drug treatment is currently lacking. Here, we address these issues using a knock-in Phospholamban p.Arg14del zebrafish model. Hearts from adult zebrafish with this mutation display age-related remodeling with sub-epicardial inflammation and fibrosis. Echocardiography reveals contractile variations before overt structural changes occur, which correlates at the cellular level with action potential duration alternans. These functional alterations are preceded by diminished Ca2+ transient amplitudes in embryonic hearts as well as an increase in diastolic Ca2+ level, slower Ca2+ transient decay and longer Ca2+ transients in cells of adult hearts. We find that istaroxime treatment ameliorates the in vivo Ca2+ dysregulation, rescues the cellular action potential duration alternans, while it improves cardiac relaxation. Thus, we present insight into the pathophysiology of Phospholamban p.Arg14del cardiomyopathy.
Original languageEnglish
Article number7151
JournalNature communications
Volume12
Issue number1
DOIs
Publication statusPublished - 1 Dec 2021

Cite this